What Hormone Receptor-Positive Means
When a breast biopsy is analyzed, the lab tests cancer cells for specific surface proteins called receptors. If the cells carry receptors for estrogen (ER), progesterone (PR), or both, the cancer is classified as hormone receptor-positive, or HR+. Research published in Cancers estimates that approximately 80 percent of breast cancers are estrogen receptor-positive, making HR+ the most common breast cancer type. Estrogen and progesterone can stimulate these cells to grow, so the goal of standard treatment is to lower those hormone signals or block their activity at the receptor level.
An HR+ diagnosis is not one single disease. It covers several subtypes based on how strongly the ER and PR receptors are expressed, whether a separate protein called HER2 is also overexpressed, how fast the cells are dividing, and the overall tumor grade. Your doctor needs all these numbers to understand your situation and choose your treatment.
Five Key Markers in Your Pathology Report
This table explains the five markers you will hear about after an HR+ breast cancer diagnosis. The American Cancer Society and the research below provide these descriptions. Your results depend on your age, menopausal status, tumor size, and lymph node status. Use this table as a starting point for talking with your oncologist, not as a tool to make decisions alone.
| Marker | Lower or Negative Result | Higher or Positive Result |
|---|---|---|
| ER (estrogen receptor) | Few or no estrogen receptors on cancer cells. Endocrine therapy is less likely to be effective on its own. | Cancer cells carry estrogen receptors. Tamoxifen or an aromatase inhibitor is typically the first treatment added. |
| PR (progesterone receptor) | ER+/PR- tumors have a modestly lower response rate to endocrine therapy than ER+/PR+ tumors. | Adds favorable prognostic information when ER is also positive. The ER+/PR+ combination is the most common HR+ presentation. |
| HER2 (HER2 protein) | Normal HER2 protein levels. No HER2-directed drug is needed. | The cancer overexpresses the HER2 protein. Targeted HER2 therapy may be added alongside endocrine treatment. |
| Ki-67 (proliferation index) | Under 20 percent: cells dividing at a slower rate, generally linked to lower Oncotype DX recurrence scores. | Over 20 percent: cells dividing faster, linked to higher recurrence scores and may influence chemotherapy decisions. |
| Histologic grade | Grade 1: cancer cells look similar to normal breast cells and tend to grow more slowly. | Grade 3: cells look very different from normal tissue and tend to grow faster. |
Ki-67 thresholds sourced from: Prediction of Oncotype DX Recurrence Score Based on Ki-67 in HR+ Early Breast Cancer, PMC 2024.
The Oncotype DX Score: What It Adds
If your tumor is HR+, HER2-negative, and caught at an early stage, your oncologist may order the Oncotype DX Breast Recurrence Score test. This 21-gene analysis examines the activity of specific genes in your cancer sample. The result is a number on a scale from 0 to 100 that estimates the likelihood of the cancer returning within 10 years. It also helps predict whether adding chemotherapy to endocrine therapy is likely to reduce that risk for you.
Research confirms that Ki-67 and histologic grade both correlate with the Oncotype DX recurrence score, but neither can replace the full 21-gene analysis because they each capture only part of the biological picture. The Oncotype DX result, combined with the markers in the table above and your lymph node status, guides one of your most important conversations with your oncologist after diagnosis. Not every newly diagnosed patient will need this test, so ask your team whether it applies to your case before expecting it to be ordered.
Standard Endocrine Treatment: The Foundation of HR+ Care
For most people with HR+ breast cancer, the core of treatment is endocrine therapy – medicines that either lower estrogen in your body or stop estrogen from attaching to cancer cells. Two main categories are used in clinical practice.
Tamoxifen blocks the estrogen receptor directly. It works for women before and after menopause. Research shows that tamoxifen cuts the annual breast cancer death rate by 31 percent in hormone receptor-positive patients. Doctors usually recommend tamoxifen for 5 to 10 years, with the exact duration based on your personal recurrence risk.
Aromatase inhibitors work differently. They block an enzyme in fat tissue that turns other hormones into estrogen. Examples include anastrozole, letrozole, and exemestane. Doctors usually prescribe these for women who have already gone through menopause. Your oncologist will decide which drug, what dose, and how long you take it based on your full situation.
If your tumor is HER2-positive in addition to HR+, your team will discuss adding a targeted HER2 drug to your treatment plan. These are prescription medications that require a clinical decision and close monitoring.
Integrative Support: What the Evidence Currently Shows
Integrative oncology does not replace endocrine therapy or any prescribed treatment. It supports standard care and aims to help estrogen metabolism and quality of life through compounds with research backing. The section below covers the most studied compound for HR+ breast cancer integrative support. Each compound includes a clinical dose from published research – this is the baseline for evaluating any supplement here.
DIM and Indole-3-Carbinol: Estrogen Metabolism Research
Diindolylmethane (DIM) forms when you digest cruciferous vegetables such as broccoli, kale, and cabbage. Indole-3-carbinol (I3C) is what’s in food before digestion converts it to DIM. Both have been studied for how they might affect estrogen metabolism in your body.
A study of 130 women on tamoxifen tested a bioavailable DIM formulation (BR-DIM) at 150 mg twice daily – 300 mg per day total – for 12 months in a randomized, double-blind, placebo-controlled trial. BR-DIM improved estrogen metabolism and sex hormone-binding globulin (SHBG) levels. However, the trial also found that DIM might lower endoxifen – the active form of tamoxifen. This means DIM could make tamoxifen less effective. The researchers said more study is needed before adding DIM to tamoxifen therapy regularly.
You must tell your doctor before starting any DIM or I3C supplement during hormone therapy. When you compare formulations, standard DIM powder does not absorb well. Enhanced-delivery forms are what the research used. Cruciferex Estrogen Detox combines DIM and I3C – the pairing most studied in estrogen metabolism research. Bring any product label to your doctor before you start.
Drug Interactions: A Critical Point for HR+ Patients on Endocrine Therapy
Supplements can interact with hormone therapy. Several change how your liver processes tamoxifen and aromatase inhibitors, which might make these drugs less effective. The following are the most common interaction risks.
- DIM might lower endoxifen – the active form of tamoxifen. Tell your doctor before you start it.
- St. John’s Wort speeds up how your body breaks down tamoxifen, which might make it less effective. Avoid it during hormone therapy.
- Grapefruit can affect CYP3A4, an enzyme that breaks down some aromatase inhibitors. Ask your pharmacist if your specific drug is affected.
- Some herbal supplements affect CYP2D6, the enzyme that converts tamoxifen to endoxifen. Ask your pharmacist to check any new supplement against your medications before you start.
To learn how to evaluate supplements for safety with hormone and chemo therapy, see the article on low-dose naltrexone and hormonal therapy safety.
Questions to Ask Your Oncology Team
Bring this list to your next appointment. Ask a caregiver to take notes if that helps.
- What is my exact ER score, PR score, and Ki-67 percentage – and what do those numbers mean for my specific subtype?
- Is my tumor HER2-negative or HER2-positive, and does that change my treatment plan?
- Do you recommend an Oncotype DX test for my case? What score range would lead you to recommend adding chemotherapy?
- Which endocrine therapy do you recommend given my menopausal status, and for how many years?
- Are there supplements I currently take that could interact with my endocrine therapy?
- Does this center offer an integrative oncology consultation or a registered dietitian with oncology experience?
Evaluating Formulation Quality
If you want to add supplements to your standard treatment, bioavailability matters. DIM and I3C need enhanced delivery systems to absorb well – standard powders may deliver far less than the doses in research. Check the Nutraceuticals section to compare ingredient labels and delivery formats. Bring any product name to your appointment for a proper clinical review.
If you take any prescription medicine – including tamoxifen, an aromatase inhibitor, or any targeted therapy – talk with your doctor and pharmacist before starting any new supplement. This also applies if you are pregnant or breastfeeding.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
